Matches in DBpedia 2014 for { <http://dbpedia.org/resource/NS-2359> ?p ?o. }
Showing items 1 to 34 of
34
with 100 items per page.
- NS-2359 abstract "NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007. A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.Another scientific article on NS-2359 was recently (2011) published. As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.".
- NS-2359 atcPrefix "none".
- NS-2359 iupacName "(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane".
- NS-2359 pubchem "11408320".
- NS-2359 thumbnail NStwothreefivenine.png?width=300.
- NS-2359 wikiPageID "22602885".
- NS-2359 wikiPageRevisionID "557545407".
- NS-2359 atcPrefix "none".
- NS-2359 c "15".
- NS-2359 cl "2".
- NS-2359 h "19".
- NS-2359 hasPhotoCollection NS-2359.
- NS-2359 iupacName "-3".
- NS-2359 molecularWeight "300.223".
- NS-2359 n "1".
- NS-2359 o "1".
- NS-2359 pubchem "11408320".
- NS-2359 smiles "Clc1cccCCC3NC2CC3".
- NS-2359 verifiedrevid "424915685".
- NS-2359 subject Category:Ethers.
- NS-2359 subject Category:Organochlorides.
- NS-2359 subject Category:Serotonin-norepinephrine-dopamine_reuptake_inhibitors.
- NS-2359 subject Category:Tropanes.
- NS-2359 type Drug.
- NS-2359 type DrugProduct.
- NS-2359 type FunctionalSubstance.
- NS-2359 comment "NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007.".
- NS-2359 label "NS-2359".
- NS-2359 sameAs m.05z_m2n.
- NS-2359 sameAs Q6955224.
- NS-2359 sameAs Q6955224.
- NS-2359 wasDerivedFrom NS-2359?oldid=557545407.
- NS-2359 depiction NStwothreefivenine.png.
- NS-2359 isPrimaryTopicOf NS-2359.